Frost & SullivanUltrasoundAffordable equipment accelerates ultrasound proliferationHand-carried ultrasound (HCU) is currently the fastest-growing product segment in the U.S. ultrasound market. Industry research has forecast the segment's revenue to more than triple by 2010. Luke Liem of Frost & Sullivan analyzes the future of ultrasound.January 25, 2004PACS/VNAPACS in Latin America: Opportunities and challengesThe Latin American market offers unique opportunities for PACS vendors looking to expand into international markets. There are some important caveats, however. Antonio García of Frost & Sullivan discusses which countries will have the financial and technological resources required for full-scale PACS implementation.August 12, 2002Nuclear MedicineRadiopharmaceutical market poised for changeAfter years of healthy revenue growth, but otherwise stagnant market and competitive activity, the U.S. radiopharmaceutical sector is poised for rapid and revolutionary change. Monali Patel of Frost & Sullivan predicts a rosy future for nuclear medicine imaging agents.July 23, 2002Advanced Visualization3-D imaging in Europe: The jewel in the crownThe European 3-D imaging market continues to grow as the technology proves its advantages over 2-D. Analyst Sumit Sharma of Frost & Sullivan discusses how an expanding range of 3-D clinical applications will become an important revenue generator for the European medical industry.May 29, 2002CTCT: A market revitalized and redefinedOn all counts, the CT market has evolved. Whether it's evaluated from the perspective of size, technology, target markets, or competitors, the CT industry has completely redefined itself. Monali Patel of Frost & Sullivan explains the evolution of CT.April 4, 2002PACS/VNAThe European PACS market: The best is yet to comeIn Europe, the role of PACS within the hospital has evolved over the years, and is now moving inexorably towards integration. Yesterday PACS was a departmental solution; today it is part of the enterprise. Tomorrow, PACS will provide the imaging layer of the electronic patient record.March 20, 2002Digital X-RayThe digital radiography market: From revolution to slow evolutionAlthough digital radiography has been touted as a virtual panacea for all that ails radiography departments -- from lost exams to the high cost of x-ray film to the shortage of radiologists and technologists -- it has so far failed to take the sluggish x-ray equipment market by storm. Antonio García of Frost & Sullivan explains why.March 18, 2002PACS/VNAPACS: The best thing to happen to RIS?The RIS industry in the U.S. is currently plagued by market saturation and marginal revenue growth. But thanks to new strategies by PACS vendors, the outlook for the RIS sector may be improving, according to a Frost & Sullivan analysis.February 17, 2002MRIRush to open: The new dynamic in high-field MRIThe MRI market has been characterized by fast-paced, continuous technological innovation from the moment Fonar installed the first commercial system in 1980. Since then, MRI scanners have become faster, smaller, quieter, safer, and easier to use. The U.S. MRI market first surpassed the $1 billion mark in 1999, and very healthy growth rates are predicted for the foreseeable future.November 22, 2001BreastMammography market stands at crossroadsScreening mammography for the early detection of breast cancer is one of radiology’s most important public health triumphs. Unfortunately, mammography is also one of a growing number of radiological procedures caught in the current funding crunch. A report by Frost & Sullivan explains how full-field digital mammography could be a way out of the financial impasse.September 24, 2001Page 1 of 1Top StoriesClinical NewsBody composition analysis, MRI safety topped 2024's most read articlesWhile COVID and radiology salaries hit the top of AuntMinnie.com's Top 10 most-read posts of 2023, they rounded out the bottom of this year's list.Practice ManagementNeiman index outperforms Charlson for predicting imaging useWomens Imaging40% of women in their 40s forgo biennial breast cancer screeningRisk ManagementPractices must comply with the Corporate Transparency ActNuclear MedicineKidneys appear to tolerate Lu-177 treatments